VERICEL CORPORATION (VCEL) Gross Margin
- Gross margin · 12 months: Value 74.56%; Formula and calculation Gross profit / revenue. Period ending 2026-06-30..
Gross margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | 74.56% | Gross profit / revenue. Period ending 2026-06-30. $228.38M ÷ $306.30M × 100 ≈ 74.56% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | 228.38M USD | Gross Profit |
| Revenue | 306.30M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | 77.92M USD | Cost of Goods and Services Sold |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2026-06-30 | $228.38M | $306.30M | $77.92M | 74.56% |
| 2026-03-31 | $218.59M | $292.09M | $73.49M | 74.84% |
| 2025-12-31 | $205.60M | $276.26M | $70.66M | 74.42% |
| 2025-09-30 | $190.97M | $258.72M | $67.75M | 73.81% |
| 2025-06-30 | $183.04M | $249.12M | $66.08M | 73.47% |
| 2025-03-31 | $173.03M | $238.54M | $65.52M | 72.54% |
| 2024-12-31 | $172.11M | $237.22M | $65.12M | 72.55% |
| 2024-09-30 | $162.12M | $226.84M | $64.73M | 71.47% |
| 2024-06-30 | $151.07M | $214.52M | $63.45M | 70.42% |
| 2024-03-31 | $144.41M | $207.78M | $63.37M | 69.50% |
| 2023-12-31 | $135.58M | $197.52M | $61.94M | 68.64% |
| 2023-09-30 | $125.32M | $185.21M | $59.90M | 67.66% |
| 2023-06-30 | $119.94M | $177.96M | $58.24M | 67.40% |
| 2023-03-31 | $112.86M | $168.86M | $56.45M | 66.83% |
| 2022-12-31 | $109.79M | $163.70M | $54.58M | 67.07% |
| 2022-09-30 | $105.57M | $158.05M | $53.69M | 66.79% |
| 2022-06-30 | $102.44M | $153.45M | $52.78M | 66.76% |
| 2022-03-31 | $106.49M | $155.30M | $51.20M | 68.57% |
| 2021-12-31 | $106.03M | $153.07M | $50.16M | 69.26% |
| 2021-09-30 | $105.64M | $150.28M | $48.18M | 70.29% |
| 2021-06-30 | $106.01M | $147.58M | $45.56M | 71.83% |
| 2021-03-31 | $90.46M | $128.92M | $41.61M | 70.17% |
| 2020-12-31 | $84.23M | $121.97M | $39.95M | 69.06% |
| 2020-09-30 | $79.39M | $117.10M | $38.95M | 67.79% |
| 2020-06-30 | $78.09M | $116.58M | $38.49M | 66.98% |
| 2020-03-31 | $83.86M | $122.72M | $38.85M | 68.34% |
| 2019-12-31 | $80.28M | $117.85M | $37.57M | 68.12% |
| 2019-09-30 | $74.18M | $109.80M | (m) | 67.56% |
| 2019-06-30 | $67.35M | $101.78M | (m) | 66.17% |
| 2019-03-31 | $61.51M | $72.85M | (m) | 84.43% |
| 2018-12-31 | $58.70M | $90.86M | $32.16M | 64.60% |
| 2018-09-30 | $50.95M | $82.87M | (m) | 61.48% |
| 2018-06-30 | $43.68M | $74.65M | (m) | 58.51% |
| 2018-03-31 | $41.68M | $72.59M | (m) | 57.42% |
| 2017-12-31 | $33.57M | $63.92M | (m) | 52.52% |
| 2017-09-30 | $27.54M | (m) | (m) | (m) |
| 2017-06-30 | $24.54M | (m) | (m) | (m) |
| 2017-03-31 | $20.78M | (m) | (m) | (m) |
| 2016-12-31 | $26.08M | $54.38M | (m) | 47.95% |
| 2016-09-30 | $25.34M | $53.28M | (m) | 47.55% |
| 2016-06-30 | $25.80M | $53.66M | (m) | 48.08% |
| 2016-03-31 | $26.96M | $54.43M | (m) | 49.54% |
| 2015-12-31 | $24.70M | $51.17M | (m) | 48.27% |
| 2015-09-30 | $24.46M | $50.45M | (m) | 48.48% |
| 2015-06-30 | $24.05M | $48.80M | (m) | 49.28% |
| 2015-03-31 | $16.78M | $39.65M | (m) | 42.34% |
| 2014-12-31 | $11.50M | $28.80M | (m) | 39.95% |
| 2014-09-30 | (m) | $14.10M | (m) | (m) |
| 2014-06-30 | (m) | $4.44M | (m) | (m) |
| 2014-03-31 | (m) | (m) | (m) | (m) |
| 2013-12-31 | (m) | $19.00K | (m) | (m) |
| 2013-09-30 | (m) | $30.00K | (m) | (m) |
| 2013-06-30 | (m) | $30.00K | (m) | (m) |
| 2013-03-31 | (m) | $27.00K | (m) | (m) |
| 2012-12-31 | (m) | $21.00K | (m) | (m) |
| 2012-09-30 | (m) | $2.00K | (m) | (m) |
| 2012-06-30 | (m) | $11.00K | (m) | (m) |
| 2012-03-31 | (m) | $11.00K | (m) | (m) |
| 2011-12-31 | (m) | $18.00K | (m) | (m) |
| 2011-09-30 | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | $89.00K | (m) | (m) |
| 2009-06-30 | (m) | $182.00K | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |